Summary
BRANSONPHARMA is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €174,472 and a net result of €30,298. Equity is growing by about 24% per year across the filed financial years. Its solvency ranks better than 21% of 9,728 sector peers (NACE 64, financial year 2025). The company has been active since 2005 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
28-12
Gazette deed
Amendment of the articles · Legal-form change · Resignations & appointmentsCapital conversion · Reserve release · Registered office clause8 facts ▸
- General meeting, 14-12-2023
- Amendment of the articles (2 times)
- Capital conversion, “statutair onbeschikbare eigen vermogensrekening” (deed in Dutch)
- Reserve release, “beschikbaar voor uitkering” (deed in Dutch)
- Other provision, “Hoofdstuk 1:Rechtsvorm en naam–zetel–voorwerp–duur” (deed in Dutch)
- Other provision, “besloten vennootschap krachtens Wetboek niet langer bestuurd door zaakvoerders maar door bestuurders, bevestiging omvorming mandaat zaakvoerders naar bestuurder…” (deed in Dutch)
- Registered office clause, “adres zetel niet meer in statuten vermeld, 1850 Grimbergen, Kerkplein 4/101” (deed in Dutch)
- Capital
About the unread acts
Of the 3 Belgian Official Gazette deeds we know for this company, 1 has been read. The other 2 have not been read yet: what they contain is neither established nor disproved here.